APPILI THERAPEUTICS INC-CL A (APLI.CA)
CA03783R1073 - Common Stock
Taking everything into account, APLI scores 0 out of 10 in our fundamental rating. APLI was compared to 37 industry peers in the Pharmaceuticals industry. APLI has a bad profitability rating. Also its financial health evaluation is rather negative. APLI is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
APLI had negative earnings in the past year.
In the past year APLI had a positive cash flow from operations.
In the past 5 years APLI always reported negative net income.
In the past 5 years APLI always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -230.61%, APLI is doing worse than 93.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -230.61% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-284.09%
ROA(5y)-195.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for APLI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
APLI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for APLI remains at a similar level compared to 1 year ago.
The number of shares outstanding for APLI has been increased compared to 5 years ago.
Compared to 1 year ago, APLI has a worse debt to assets ratio.
2.2 Solvency
APLI has an Altman-Z score of -91.64. This is a bad value and indicates that APLI is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of APLI (-91.64) is worse than 96.97% of its industry peers.
APLI has a debt to FCF ratio of 146.50. This is a negative value and a sign of low solvency as APLI would need 146.50 years to pay back of all of its debts.
With a Debt to FCF ratio value of 146.50, APLI perfoms like the industry average, outperforming 54.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 146.5 | ||
| Altman-Z | -91.64 |
ROIC/WACCN/A
WACC11.87%
2.3 Liquidity
A Current Ratio of 0.11 indicates that APLI may have some problems paying its short term obligations.
With a Current ratio value of 0.11, APLI is not doing good in the industry: 90.91% of the companies in the same industry are doing better.
APLI has a Quick Ratio of 0.11. This is a bad value and indicates that APLI is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of APLI (0.11) is worse than 84.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.11 | ||
| Quick Ratio | 0.11 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 50.73% over the past year.
The Revenue for APLI has decreased by -26.15% in the past year. This is quite bad
EPS 1Y (TTM)50.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.7%
Revenue 1Y (TTM)-26.15%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-98.62%
3.2 Future
Based on estimates for the next years, APLI will show a decrease in Earnings Per Share. The EPS will decrease by 0.00% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0%
EPS Next 2Y0%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for APLI. In the last year negative earnings were reported.
Also next year APLI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
The rest of the industry has a similar Price/Free Cash Flow ratio as APLI.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 68.19 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for APLI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
APPILI THERAPEUTICS INC-CL A
TSX:APLI (1/14/2025, 7:00:00 PM)
0.04
+0 (+14.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners11.84%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap4.85M
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 9.8 | ||
| P/FCF | 68.19 | ||
| P/OCF | 66.89 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.03
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)0
FCFY1.47%
OCF(TTM)0
OCFY1.5%
SpS0
BVpS-0.11
TBVpS-0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -230.61% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 14.38% |
ROA(3y)-284.09%
ROA(5y)-195.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 146.5 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 14.02% | ||
| Cap/Sales | 0.28% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.11 | ||
| Quick Ratio | 0.11 | ||
| Altman-Z | -91.64 |
F-Score5
WACC11.87%
ROIC/WACCN/A
Cap/Depr(3y)72.52%
Cap/Depr(5y)63.51%
Cap/Sales(3y)1.2%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.7%
EPS Next Y0%
EPS Next 2Y0%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-26.15%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-98.62%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y100.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y100.41%
OCF growth 3YN/A
OCF growth 5YN/A